Navigation Links
Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
Date:11/5/2013

BALTIMORE, Nov. 5, 2013 /PRNewswire/-- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO).  Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts.  Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008.

Under her leadership, Alba Therapeutics established a collaborative funding agreement on February 9, 2011 with Cephalon Pharmaceuticals (now Teva Pharmaceuticals) and has taken a leading role in advancing multiple clinical studies in Celiac Disease.  The company has conducted seven clinical trials in subjects with Celiac Disease and is currently conducting a large Phase IIb trial with the lead compound Larazotide Acetate. 

"Ms. Perrow brings a wealth of global experience and leadership with a proven track record of success in both biotech and pharmaceutical companies," said Bruce Peacock Co-Chairman of Alba. "Wendy is a key member of our leadership team, driving deal making as well as clinical and financial strategy and her experience in leading successful research and development and commercial infrastructures has been invaluable to Alba."

Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global and U.S. marketing for Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer and business leader, she has led U.S. and Global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.

"Throughout her career, Ms. Perrow has demonstrated a true passion and commitment to bring new scientific advances and medications to help improve the standard of care for patients who have rare and serious conditions around the globe," said Matt Zuga Co-Chairman of Alba.  "With her broad experience and proven leadership across research, development, and commercialization, we have been able to accelerate Alba's mission to create medicines for patients with Celiac Disease.  Her breadth of experience in building successful companies and establishing strong collaborations is a tremendous asset to Alba Therapeutics as we continue to establish our leadership position in the Celiac Disease field."

Ms. Perrow holds a bachelor's degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.

About Alba
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland.


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and the S&P ... Jones Industrial Average managed to stay in green. Losses were ... Stock-callers this morning to look at the performances of the ... Smith & Nephew PLC (NYSE: SNN ), Nxstage ... Inc. (NASDAQ: KOOL ). You can access our ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
(Date:11/30/2016)... , Nov 30, 2016 Research and Markets ... Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... and the skull. In healthy individuals, it is circulated though the brain ... cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in ... fits into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started ... how the details line up exactly with Bible Prophecy – a protected way for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, Inc., ... $6.0 million in an initial round of funding. The round was led by ... caregivers can receive far better care through the application of the best technologies ...
(Date:12/2/2016)... ... 2016 , ... Today CloudMine, a secure, cloud-based platform that ... best Sales Team of 2016 as part of the 2016 SIIA Company CODiE ... & Information Industry Association (SIIA), the principal trade association for the software and ...
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
Breaking Medicine News(10 mins):